Top 50 Life Science VC (Venture Capital) Funds in United States in October 2024
A list of 50 VC (Venture Capital) funds that invest in Life science startups based in United states. We rank investors based on the number of investments they made in Life science companies from United states. We update this investor list every month.Top 50 Life Science VC (Venture Capital) Funds in United States in October 2024
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, China, United Kingdom
Portfolio highlights
- Vilya — Vilya is a computational biotechnology company creating a novel class of medicines to precisely target disease biology.
- Moleculent — Moleculent is adding a functional layer of biology to pave the way for unparalleled advancements in biological research.
- Rippl Care — Dementia care for seniors, ready when you are
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates.
HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Convertible Note, Pre-Seed
- United States, India, United Kingdom
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more
Investment focus
- Biotechnology, Health Care, Life Science
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Totus Medicines — Applying revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases.
- SeLux Diagnostics — SeLux Diagnostics is a developer of the Next-Generation Phenotyping (NGP) platform that enables personalized antibiotic therapies for patients. The company was founded in 2014 and is based in Charlestown, MA.
- Elephas — Elephas is a live tumor imaging company developing novel cancer diagnostic solutions to predict treatment outcomes and accelerate drug development.
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, France, Canada
Portfolio highlights
- Umaro Foods — Umaro Foods specializes in developing a plant-based protein source from ocean-farmed seaweed.
- TwoStep Therapeutics — TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors.
- Bright Peak Therapeutics — Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases. At Bright Peak, they are creating innovative cytokine therapeutics that are uniquely engineered to precisely control and expand desired biological properties.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
- Exsilio Therapeutics — Exsilio's method is based on naturally occurring genetic elements that can accurately insert new genes into cells via RNA intermediate templates. Exsilio employs predictive in-silico modeling and wet lab-based experiments to create such elements for accurate insertion of therapeutic genes into safe harbor regions of disease-relevant cells.
- Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Series A
- United States, United Kingdom, China
Portfolio highlights
- Idrx — IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies.
- MBX Biosciences — Homepage - MBX Biosciences
- Navigator Medicines — Leading the advancement of biologics for targeted immune regulation & restoration.
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States
Portfolio highlights
- Marea Therapeutics — Marea Therapeutics is a clinical-stage biotechnology firm that uses the most recent advancements in human genetics to create first-in-class, next-generation medications for cardiometabolic illnesses.
- Candid Therapeutics — Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
- Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
We are deep tech venture capital.
Show more
Investment focus
- Software, Artificial Intelligence, Health Care
- Seed, Series A, Series B
- United States, Canada, United Kingdom
Portfolio highlights
- Noetik — Noetik is an AI-native biotechnology company. Our mission is to leverage advanced machine learning methods to discover and develop cancer immunotherapies.
- Twelve — Twelve is a carbon transformation company converting captured carbon dioxide into valuable chemicals, fuels, and other essential products. Their technology eliminates emissions by turning CO2 into essential products that are made from fossil fuels. They specialize in the fields of CO2 electrocatalysis and electrochemical reactor design.
- Zap Energy — Zap Energy's fusion reactor stabilizes plasma using sheared flows rather than magnetic fields. Driving electric current through the flow creates the magnetic field, which confines and compresses the plasma. The higher the current, the greater the pressure and density in the plasma. Zap Energy's reactor is the least expensive, mostcompact, most scalable solution with the shortest path to commercially viable fusion.
WE BACK HEROES using technology to solve the world's biggest problems
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, Germany, Canada
Portfolio highlights
- Aalo Atomics — Creating abundant and dependable clean energy to power humanity for generations.
- BillionToOne — We are a team at the forefront of disease detection focused on moving Prenatal Screening and Liquid Biopsy forward.
- Waypoint Bio — Waypoint's proprietary spatial multi-omics platform enables us to solve critical issues around understanding how cell therapies navigate the three-dimensional tumor microenvironment and allow the measurement of cell-to-cell interactions.
DIGITAL HEALTH / AI
DIGITAL HEALTH / AI GENE / CELL THERAPIES
NASDAQ: RCKT GENE / CELL THERAPIES
NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS
SYNTHETIC
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, United Kingdom, Brazil
Portfolio highlights
- SyntaxBio — SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
- Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
- Foresight Diagnostics — We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.
8VC seeks to enable industry transformation. In a wave of creative destruction, they believe emerging platforms will replace the decades-old technology infrastructure behind many industries, promoting greater innovation and prosperity.
Show more
Investment focus
- Software, Health Care, Information Technology
- Seed, Series A, Series B
- United States, Canada, United Kingdom
Portfolio highlights
- Deep Fission — Innovative US nuclear energy company Deep Fission launches underground scalable 15MW, affordable, small modular reactors.
- Candid Health — At Candid Health, we make medical billing easy so healthcare providers can get paid. Our platform automates the complexity out of revenue cycle so you never have to make the same mistake twice.
- Landbase — Landbase combines leading agentic AI with human expertise to intelligently automate your Go-To-Market
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Funding Round
- United States, Canada
Portfolio highlights
- Endogenex — DyaMX is an early stage medical device company focused on the treatment of Type 2 Diabetes
- AtaCor Medical — AtaCor Medical - Designing innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most.
- Veralox Therapeutics — Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
Supporting early stage Life Science startups driving patient impact. Born from our collective experience as founders, we set out to build the fund we wanted to raise from....
Show more
Investment focus
- Biotechnology, Health Care, Life Science
- Seed, Series A, Pre-Seed
- United States
Portfolio highlights
- Xilis — Xilis is an oncology and precision health company that diagnoses cancer and finds the right treatment. The company uses “micro-organoids” to make thousands of 3D replicas of a patient’s tumor in about six days, which the company says can be used for testing for drug compatibility faster. It was founded in 2019 and is headquartered in Durham,North Carolina.
- Elegen — Elegen is powering the bioeconomy with high-accuracy DNA synthesis that delivers industry-leading speed, length, and quality.
- Zafrens — Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States.
Powering Breakthroughs in Life Sciences
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series A, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- AstronauTx — AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
- Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
- Frontier Medicines — Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target undruggable therapies
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Disc Medicine — Disc Medicine is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors.
- GRO Biosciences — GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency,stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.
- Kailera Therapeutics — Kailera Therapeutics is a clinical-stage biotechnology company that provides revolutionary therapies for treating obesity and related diseases.
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries.
5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- RareCyte — Rarecyte provides precision medicine solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics.
- TMRW Life Sciences — TMRW helps patients and clinics safely store their eggs and embryos
- Tectonic Therapeutic — Tectonic and AVROBIO have completed their anticipated merger.Please follow this link to our press release for additional information.
Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.
Show more
Investment focus
- Biotechnology, Health Care, Non Profit
- Funding Round, Series A, Seed
- United States, China, Ghana
Portfolio highlights
- Insamo — Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity.
- Monod Bio — Monod Bio l Simple. Powerful. Biosensors for Medicine & Biotech.
- Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more
Investment focus
- Software, Information Technology, Internet
- Series A, Seed, Series B
- United States, United Kingdom, Canada
Portfolio highlights
- 11x — Onboard the AI workforce from the future and 11x your productivity today
- Prepared — We are harnessing the power of everyday technology to enhance the way that people communicate during emergencies.
- Salient Motion — A next-generation supplier for aerospace and defense, specializing in advanced electric propulsion.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, China, Israel
Portfolio highlights
- Chemomab — Pioneering Innovative Treatments for Patients with Fibrosis-Related Diseases
- MBX Biosciences — Homepage - MBX Biosciences
- Brenig Therapeutics — Brenig Therapeutics develops therapies for neurodegenerative disorders.
Rev1 Ventures provides seed stage venture capital funding in Columbus, Ohio along with startup services, space, mentoring, and connections. Learn more!
Show more
Investment focus
- Software, Health Care, Information Technology
- Seed, Series A, Funding Round
- United States, Germany
Portfolio highlights
- HubiFi — SaaS Financial Automation & Analysis for High Transaction Businesses
- Myoptechs — Myoptechs, a pediatric ophthalmic medical device startup in the clinical stage, has made advancements in its fund-raising and clinical research program. The company creates innovative soft contact lenses and spectacles that reduce the growth of myopia while offering incredibly clear vision.
- Niobium Microsystems — Next-Gen Confidential Computing
GV supports innovative founders moving the world forward.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Series B, Seed
- United States, United Kingdom, Switzerland
Portfolio highlights
- Rippl Care — Dementia care for seniors, ready when you are
- MOLO MOLO PAY — MOLO MOLO PAY est la première expérience d'achat basée sur l'épargne intégrée aux commerçants en Afrique francophone. Économisez maintenant, achetez plus tard.
- Nym — Nym Health leverages advanced AI for medical coding, revolutionizing accuracy and speed within revenue cycle management. Discover the difference.
KdT Ventures is the standard for early-stage frontier science investing.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, Israel, Germany
Portfolio highlights
- Marigold Health — Marigold Health is an anonymous social network where people with mental health and substance use conditions support each other.
- Radar Therapeutics — Precision-targeted, smart therapies to conquer the world's most intractable diseases.
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
Longwood creates and invests in science-based companies that develop novel solutions for important medical problems
Show more
Investment focus
- Biotechnology, Therapeutics, Health Care
- Series A, Series B, Series C
- United States, United Kingdom, Italy
Portfolio highlights
- Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
- Progentos Therapeutics — Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
- BridgeBio Oncology Therapeutics — BridgeBio Oncology Therapeutics operates as a biopharmaceutical company.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
- Renalys Pharma — Renalys Pharma is a private, late-stage clinical biopharmaceutical firm in Japan dedicated on developing new therapies that address unmet needs in the management of renal illness in Japanese and Asian patients.
- Zenas BioPharma — Enabling patients with autoimmune diseases to reimagine life
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Switzerland, Canada
Portfolio highlights
- SixPeaks Bio — SixPeaks is developing a pipeline of medicines for healthy weight loss.
- Borealis Biosciences — Borealis Biosciences was founded on the premise that a convergence of scientific and translational breakthroughs is enabling the field of RNA medicines to treat kidney diseases and beyond. The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.
- Bright Peak Therapeutics — Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases. At Bright Peak, they are creating innovative cytokine therapeutics that are uniquely engineered to precisely control and expand desired biological properties.
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts.
The firm operates as a multi-fund investment platform, covering growth equity, private
equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series C, Series A
- United States, China, United Kingdom
Portfolio highlights
- Zenas BioPharma — Enabling patients with autoimmune diseases to reimagine life
- Ajax Therapeutics — Ajax Therapeutics is an NYC-based biotechnology company applying computational chemistry and structure-based technologies to develop novel small molecules for hematologic malignancies
- Unicycive Therapeutics — Unicycive Therapeutics (UNCY) invents and develop medications that make a meaningful difference in the lives of kidney patients and their caregivers.
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Seed, Series B
- United States, Canada, United Kingdom
Portfolio highlights
- Magie — Magie is WhatsApp's first smart account, designed for people who understand the value of their time.Magie pays your invoices using WhatsApp and you may communicate with her via messages, audio, or photographs without ever having to enter into an app. Magic.
- JOYA — JOYA is the first employee skincare and wellness benefit platform. The company's goal is to provide tailored access to services such as skin cancer screenings, skin condition treatment, anti-aging, acne, and hair loss care from reputable physicians at an accessible cost.
- Impulse Space — Economical and nimble last-mile space payload delivery
ATP, a global leader in life sciences venture capital, is developing the next generation of transformative biotechnology companies. ATP creates science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines. The firm provides flexible capital, strategicinsight, and operational resources to build sustainable, research-driven enterprises. ATP invests in its portfolio companies from seed stage through IPO and beyond and supports their management teams in strategic transactions and synergistic business combinations.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Canada, United Kingdom
Portfolio highlights
- Ascidian Therapeutics — Ascidian Therapeutics is a biotechnology company intended for medical use in medical and clinical gene therapy.
- Red Queen Therapeutics — Staying ahead of viral threats with new innovations in antiviral therapy
- Deep Apple Therapeutics — Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented speed and exceptional acumen.
Venture investing in Food, Health, and AgTech. A generational investment thesis. Food is Health is longevity
Show more
Investment focus
- Biotechnology, Health Care, Agriculture
- Seed, Series A, Series B
- United States, Australia
Portfolio highlights
- MEND — Mend is the scientifically proven way to heal and enhance your body faster.
- Triplebar — Triplebar provides sustainability, biotechnology, and synthetic biology research.
- Pluton Biosciences — The miniscule organisms Pluton Biosciences discover possess the power to create global change. Pluton quickly and inexpensively taps into the diverse world of bacteria, fungi and viruses to discover next-generation products for carbon sequestration, agriculture, pharmaceutical, biomaterials and bioremediation.Pluton Bioscience's discoveryprocess generates diverse commercialization options, including: Organisms (biological products), Small Molecule Chemistries (fermentable and non-fermentable) and New Traits (scale dependent).
Foundational partners to ambitious founders at every stage of company-building.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series B, Series A, Series C
- United States, India, China
Portfolio highlights
- Agree.com — Agree.com is the best solution for creating and managing contracts, streamlining negotiations, enhancing compliance, optimizing workflows, and converting more customers — all within one intuitive platform. View edits, track signatures, and get alerted on all upcoming key milestones. Include free, one-click e-signatures with identity verification onevery agreement. Increase deal velocity and drive revenue impact with integrated payments.
- Sakana AI — We are creating a new kind of foundation model based on nature-inspired intelligence.
- World Labs — World Labs is an AI startup that can analyze visual data with comprehension akin to a person's, a substantial advancement above existing capacities.
Playground is an early-stage investment firm that helps old and new investors and entrepreneurs working at the intersection of bits, atoms, and AI. It focuses on investment, innovation, connected hardware, artificial intelligence, and robotics.
Show more
Investment focus
- Software, Robotics, Artificial Intelligence
- Series A, Seed, Series B
- United States, Canada, France
Portfolio highlights
- Anjuna — Anjuna confidential cloud software establishes a secure enclave that isolates and encrypts applications and data in runtime, at rest, and on the network for end-to-end data protection
- Insamo — Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity.
- Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more
Investment focus
- Biotechnology, Artificial Intelligence, Software
- Series A, Series B, Seed
- United States, United Kingdom, Canada
Portfolio highlights
- Notpla — We are a combination of designers and chemists, engineers and entrepreneurs. We’re hard to define because what we’re doing hasn’t been done before. We create advanced packaging solutions that disappear, naturally.
- Medal — Gamers live here. Medal is the best way to record, clip, edit, and share your gaming clips and videos. Clip, Edit, Share, and Relive your gaming moments.
- ZeroAvia — ZeroAvia is producing the world's first practical zero emission aviation powertrain, initially targeting 20-seat airplanes to start replacing dirty jet fuel in regional transport
The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, United Kingdom, Spain
Portfolio highlights
- DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team Latest News See more Our Work OUR APPROACH ABOUT DIABETES
- Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
- MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States
Portfolio highlights
- InduPro — InduPro is a biotechnology company that specializes in protein therapeutics and cell-surface platform technologies.
- Kenai Therapeutics — Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders. The company provides off-the-shelf neuron replacement medicines as effective disease-modifying treatments for neurological disorders, providing doctors with techniques to treat diseases like Parkinson's.
- Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Series A
- United States, United Kingdom, Australia
Portfolio highlights
- Spear Bio — Successive Proximity Extension Amplification Reaction (SPEAR) technology from Spear Bio enables ultra-sensitive biomarker detection using ultra-small samples.
- Element Biosciences — Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets. We are developing a modular and high-performing DNA sequencing platform that will deliver high quality data, workflow flexibility, and make next-generation sequencing technology more accessible. Our proprietaryapproach to improve the signal-to-noise ratio allows us to provide groundbreaking innovations in surface chemistry, instrumentation and biochemistry to drastically decrease the run cost and capital cost while delivering high sequencing data quality.
- Foresight Diagnostics — We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Seed, Series A, Funding Round
- United States, Israel, Canada
Portfolio highlights
- AmpUp — Commercial electric vehicle (EV) charging network solutions made simple for everyone. Easily manage and analyze EV charging data from a single dashboard.
- Oxylus Energy — Oxylus Energy provides new carbon utilization technology for the generation of e-fuels It strives to make CO2 capture and conversion competitive, scalable, and circular for a decarbonized future.
- Halda Therapeutics — Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states.
Artis Ventures has spent over a decade backing bold teams who take the hard path, building market-defining companies to re-shape, re-invent, and re-make industries.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Series A, Series B, Seed
- United States, India, Germany
Portfolio highlights
- Rad AI — Made for Radiologists, by Radiologists. Empowering radiologists with AI to save time, reduce burnout, and improve patient care.
- Eko Health — At Eko every digital stethoscope from Eko comes with smart disease detection capabilities to help healthcare professionals confidently identify and diagnose heart and lung disease during physical exams.
- Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Breakout Ventures is a new, early stage fund that backs bold scientist entrepreneurs working at the intersections of technology, biology, materials, and energy.
Show more
Investment focus
- Biotechnology, Life Science, Therapeutics
- Seed, Series B, Series A
- United States
Portfolio highlights
- Parallel Bio — Using the immune system to cure disease. Parallel Bio uses a human immune system in a dish and AI to discover drugs more likely to work in patients.
- TFC Therapeutics — TFC Therapeutics is a biotechnology company developing novel biologics to target and eliminate key drivers of cancer.
- EnPlusOne Biosciences — EnPlusOne Biosciences provides innovative solutions for emerging RNA therapeutics.
We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series C, Series A
- United States, Canada, United Kingdom
Portfolio highlights
- Mirai Bio — Mirai Bio has developed an open platform powered by AI to address the main drawbacks and manufacturing to develop the future of genetic medicine.
- Inari — Inari is a biotech seed company that embraces diversity in every aspect of its business to drive innovation and help build a new food system. Our technology matches the complexity of nature using predictive design and multiplex gene editing to unlock the full potential of seed. We are always innovating, pushing the boundaries of what’s possible.Our SEEDesign platform is our point of distinction, using unsurpassed technology to enhance any crop for any geography to develop step-change products with a clear go-to-market approach.
- Prologue Medicines — Prologue is systematically discovering the therapeutic potential of secreted proteins tuned through millennia of natural evolution to rapidly create powerful new medicines.
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.Cormorant Asset Management was founded in 2013 and is based in Boston, Massachusetts, UnitedStates.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series C, Series A
- United States, China, Switzerland
Portfolio highlights
- GondolaBio — GondolaBio researches, develops and manufactures pharmaceutical products.
- Navigantis — Navigantis empowers physicians to deliver uncompromised neurovascular care by creating a new frontier in surgical robotics.
- GC Therapeutics — Discover GC Therapeutics, a pioneer in scalable, cutting-edge cell therapies designed to revolutionize treatment across a broad range of therapeutic areas.
Investing in early-stage companies solving the biggest science and engineering challenges since 2014.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Seed, Series B
- United States, Austria, Israel
Portfolio highlights
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
- Progentos Therapeutics — Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
- Esper Satellite Imagery — Welcome to Esper Satellite Imagery. Enjoy your Stay.
We invest in companies that are advancing the field of genomics and pioneering new applications in healthcare, agriculture, environmental science, and personal
Show more
Investment focus
- Biotechnology, Health Care, Life Science
- Series A, Series B, Series C
- United States, United Kingdom, France
Portfolio highlights
- SyntaxBio — SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
- Attovia Therapeutics — Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated.
- Predicta Biosciences — Predicta Biosciences is a precision oncology firm that integrates multiomics and liquid biopsies to create diagnostic tools and therapies. They also have an in-house pipeline for novel immunotherapy targets in pre-clinical stages.
Pear VC partners with entrepreneurs from day zero to build category-defining companies.
Show more
Investment focus
- Software, Artificial Intelligence, Health Care
- Seed, Series A, Pre-Seed
- United States, Brazil, Colombia
Portfolio highlights
- ProhostAI — AI-powered operating system for short-term rental hosts
- Voyage AI — Voyage AI provides cutting-edge embedding models and rerankers for search and retrieval
- GC Therapeutics — Discover GC Therapeutics, a pioneer in scalable, cutting-edge cell therapies designed to revolutionize treatment across a broad range of therapeutic areas.
O'Reilly AlphaTech Ventures (OATV) is in the business of funding disruptors, innovators, and hackers of the status quo. From open source to the early days of the web and its recent resurgence, O'Reilly Media has played a key role as trend spotter and advocate for putting world-changing technologies on the map. OATV effort is to bring thelegacy, resources, and relationships of O'Reilly to each investment they make.
Show more
Investment focus
- Software, E-Commerce, Analytics
- Series A, Seed, Series B
- United States, United Kingdom, Canada
Portfolio highlights
- Pachama — Harnessing AI to drive carbon capture and protect global forests
- Paintbrush — Paintbrush provides access to funding for idea-stage founders who are too early for other options.
- Impart Security — Real-time API Security spanning discovery, monitoring, and enforcement.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, China, Italy
Portfolio highlights
- Mozart Therapeutics — The company intended to focus on developing novel immune engagers.
- Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
- DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
Khosla Ventures invests in companies that are bold, early and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs. Headquartered in Menlo Park, Calif., Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech,digital health, medtech and diagnostics, therapeutics and frontier technology.
Show more
Investment focus
- Software, Health Care, Artificial Intelligence
- Series A, Series B, Seed
- United States, India, United Kingdom
Portfolio highlights
- Vahan — Vahan's AI-Driven virtual assistant helps field sales teams and frontliners do better work at scale. A web-based dashboard allows employers to track usage data that can be used for business intelligence. Their virtual assistant is completely customizable to align with employers' support, training, communication, and reporting needs.
- Synex Medical — Synex Medical develops non-invasive blood testing technology. This portable device will allow users to monitor metabolite concentrations without having to penetrate skin. They use a miniaturized magnetic resonance system to detect blood metabolites. The system only consists of magnets and radio waves, meaning there are no negative health effects.
- Vahan.ai — Vahan uses Artificial Intelligence to match job seekers with employers inside messaging apps
The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Funding Round, Series B
- United States, France, Italy
Portfolio highlights
- vTv Therapeutics — vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.vTv Therapeutics has a pipeline of small molecule clinicaland pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company.The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology.vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo.Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification.vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.
- SAB Biotherapeutics — A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats.
- Cour Pharmaceuticals Development — COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance...
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more
Investment focus
- Software, Biotechnology, Health Care
- Series A, Series B, Series C
- United States, United Kingdom, Israel
Portfolio highlights
- Nagish — Nagish captions your phone calls and empowers you to talk using text or voice. It's fast, private, and free.
- Aim Security — Aim is the industry guide to secure GenAI adoption, empowering security leaders to drive business productivity while ensuring proactive protection for all GenAI use cases.
- Reibus — Reibus is the leading platform for buying and selling steel and other metals, with end-to-end services including logistics and financing.
We are an early-stage venture capital firm investing in transformative companies harnessing information growth and computing power to change the world.
Show more
Investment focus
- Software, Machine Learning, Artificial Intelligence
- Series A, Seed, Series B
- United States, Canada, Mexico
Portfolio highlights
- Gameto — Gameto is a new breed of biotechnology company in female reproductive longevity
- Etched.ai — Transformers etched into silicon. By burning the transformer architecture into our chips, we're creating the world's most powerful servers for transformer inference.
- Xaira Therapeutics — Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research tobetter understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.
Vida Ventures’ mission is to bring science to life by advancing transformative biomedical innovations that have the potential to make a meaningful impact on the lives of patients. They want to do well by doing good for others. Vida Ventures is a bicoastal life sciences company building and investment firm, founded in 2017 by a group of scientists,physicians, entrepreneurs, and investors who are passionate about building and funding breakthroughs in biomedicine .
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, China, India
Portfolio highlights
- Candid Therapeutics — Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
- Tectonic Therapeutic — Tectonic and AVROBIO have completed their anticipated merger.Please follow this link to our press release for additional information.
- Scorpion Therapeutics — We are developing drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to improve their safety and efficacy.
Investors by industry
Energy
Climate
Health Care
Gaming
Hardware
Artificial intelligence
Impact
Proptech
Marketplace
EdTech
Sustainability
Community
Venture Capital
Beauty
B2B
FinTech
Photography
Finance
Real Estate
Google
Big Data
Web3
Consumer
Clean Energy
Oil and Gas
Video Games
Biotech
Food and Beverage
Publishing
Education
Social Media
Payments
Medical
Fashion
Organic Food
Email
Retail
Art
Financial Services
Infrastructure
Platforms
Wellness
Mobile Advertising
Music
Biotechnology
Mobile
Hospitality
Fitness
Franchise
Travel
Recruiting
Social Network
Cannabis
Wine And Spirits
Local
Internet
Medical Device
Digital Media
Crowdfunding
Construction
Social
Automotive
Manufacturing
CleanTech
eSports
Transportation
Mobile Apps
Sports
InsurTech
Enterprise Software
Enterprise
Legal
Android
Life Science
LGBT
Theatre
Film
SaaS
Non Profit
Renewable Energy
Sporting Goods
Restaurants
Social Impact
Software
Celebrity
Agriculture (agtech)
Cryptocurrency
Media (entertainment)
Facebook
Blockchain
Investors by country
India
Germany
South Korea
United Kingdom
Australia
Ireland
New Zealand
Canada
United States
Spain
Indonesia
Singapore
South Africa
Africa
Qatar
Europe
LATAM
Middle East
Sri Lanka
Asia
Armenia
Vietnam
China
Japan
Saudi Arabia
Brazil
Oceania
Czech Republic
Ecuador
Barbados
Costa Rica
Finland
Belarus
France
Estonia
Hong Kong
Denmark
Gibraltar
Chile
Bermuda
Belize
Georgia
Greece
Egypt
Hungary
Ethiopia
Faroe Islands
Algeria
Ghana
Belgium
Croatia
Bulgaria
Bahrain
Morocco
Malta
Mali
Malaysia
Italy
Peru
Lithuania
Myanmar
Lebanon
Kuwait
Cayman Islands
Cambodia
Israel
Panama
Mexico
Turkey
Serbia
Kazakhstan
Rwanda
Liberia
El Salvador
Jersey
Philippines
Venezuela
Ukraine
Norway
Portugal
Sierra Leone
Zimbabwe
Sweden
Mauritius
Taiwan
Senegal
Kenya
Uruguay
Uganda
Tunisia
San Marino
Liechtenstein
Slovenia
Zambia
Nicaragua
Uzbekistan
Russian Federation
Seychelles
Thailand
Dominican Republic
Puerto Rico
Tajikistan
Togo
Nigeria
Poland
Tanzania
United Arab Emirates
Honduras
Bolivia
Isle of Man
Azerbaijan
Luxembourg
Namibia
Iceland
Albania
Pakistan
Iraq
Bahamas
Grenada
Jordan
Romania
Latvia
Argentina
Bangladesh
Cyprus
Oman
Austria
Cameroon
Switzerland
Colombia
Marshall Islands
Guatemala
VC (Venture Capital) Funds in United States by industry
Transportation
FinTech
Enterprise
Consumer
Health Care
Biotech
Impact
Climate
SaaS
Energy
Marketplace
Sustainability
Proptech
Community
Artificial intelligence
Gaming
Venture Capital
Retail
Crowdfunding
Financial Services
LGBT
Oil and Gas
Film
Publishing
Cryptocurrency
Education
Wine And Spirits
Payments
Food and Beverage
Video Games
Medical
Restaurants
Franchise
Wellness
EdTech
Hardware
Email
Social Media
Digital Media
Manufacturing
Art
Celebrity
Theatre
Blockchain
Social Impact
Android
Mobile
Legal
Google
Software
Non Profit
Local
Enterprise Software
Sports
Finance
eSports
Hospitality
Automotive
CleanTech
InsurTech
Travel
Biotechnology
Cannabis
Platforms
Mobile Advertising
Infrastructure
Real Estate
Social
Fashion
Web3
Photography
Life Science
Sporting Goods
Clean Energy
Big Data
Construction
Medical Device
Mobile Apps
B2B
Social Network
Fitness
Renewable Energy
Music
Internet
Beauty
Media (entertainment)
Agriculture (agtech)
Facebook
Organic Food
Recruiting